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Abstract
Neurodegenerative diseases are an enormous public health problem, affecting tens of millions of people worldwide. Nearly 
all of these diseases are characterized by oligomerization and fibrillization of neuronal proteins, and there is great interest 
in therapeutic targeting of these aggregates. Here, we show that soluble aggregates of α-synuclein and tau bind to plate-
immobilized PrP in vitro and on mouse cortical neurons, and that this binding requires at least one of the same N-terminal 
sites at which soluble Aβ aggregates bind. Moreover, soluble aggregates of tau, α-synuclein and Aβ cause both functional 
(impairment of LTP) and structural (neuritic dystrophy) compromise and these deficits are absent when PrP is ablated, 
knocked-down, or when neurons are pre-treated with anti-PrP blocking antibodies. Using an all-human experimental para-
digm involving: (1) isogenic iPSC-derived neurons expressing or lacking PRNP, and (2) aqueous extracts from brains of 
individuals who died with Alzheimer’s disease, dementia with Lewy bodies, and Pick’s disease, we demonstrate that Aβ, 
α-synuclein and tau are toxic to neurons in a manner that requires  PrPC. These results indicate that PrP is likely to play an 
important role in a variety of late-life neurodegenerative diseases and that therapeutic targeting of PrP, rather than individual 
disease proteins, may have more benefit for conditions which involve the aggregation of more than one protein.
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iN  IPSC-derived induced neurons
iPSC  Induced pluripotent stem cell
IR  Immunoreactive
LTP  Long-term potentiation
mAb  Monoclonal antibody
mGluR  Metabotropic glutamate receptors
MPN  Mouse primary neurons
PD  Parkinson’s disease
PiD  Pick’s disease
PRNP  Prion protein gene
PrP  Prion protein
PrPC  Cellular prion protein
PrPSc  Prion protein-scrapie
PSP  Progressive supranuclear Palsy
SAAs  Soluble α-synuclein aggregates
SBA  Soluble Aβ aggregates
SEC  Size exclusion chromatography
SPA  Soluble protein aggregates
STAs  Soluble Tau aggregates
TBS  Theta-burst stimulation
ThT  Thioflavin T
WT  Wild type
Introduction
The presence of macroscopic protein aggregates is pathog-
nomonic for most common neurodegenerative disorders [78, 
82]. Alzheimer’s disease (AD) is characterized by two types 
of protein deposits: plaques composed of amyloid β-protein 
(Aβ) and tau-containing neurofibrillary tangles [36, 59]. Tau 
aggregates are also found in progressive supranuclear palsy 
(PSP), corticobasal degeneration (CBD) and Pick’s disease 
(PiD) [5, 50, 70]. In Parkinson’s disease (PD) and dementia 
with Lewy bodies (DLB), α-synuclein (αSyn) accumulates 
within neurons as Lewy bodies and Lewy neurites [83]. The 
end-stage aggregates present in these various diseases are 
β-sheet-rich and fibrillar in nature, but have distinct ultras-
tructures [27, 28, 30, 57, 72]. Whether these thermodynami-
cally stable aggregates drive pathogenesis or merely reflect 
aberrant processing of the parent proteins is controversial, 
and significant evidence suggests that soluble aggregates 
(often referred to as oligomers) are the primary mediators 
of neuronal dysfunction [18, 88].
Certain assemblies of Aβ, αSyn and tau have been shown 
to be potent neurotoxins [22, 24, 26, 29, 61, 67, 85], but to 
date the activity of Aβ assemblies has been the most inten-
sively studied, with more than a dozen putative receptors 
proposed [8]. Of these candidates, the cellular prion pro-
tein  (PrPC) has more supportive evidence than most [81]. 
All published studies on the Aβ-PrP interaction have con-
cluded that binding is high affinity (sub-nanomolar) and 
oligomer-specific, and many have found that binding to PrP 
mediates a toxic response [19, 31, 32, 53, 62, 66, 73, 84, 91, 
93]. However, there have been reports of deleterious effects 
of Aβ that do not require  PrPC expression [4, 15, 20, 51]. 
The likely explanation for these conflicting results lies in 
the lack of standardization of the Aβ preparations used and 
the unrealistic expectation that all forms of Aβ should cause 
toxicity by a PrP-dependent mechanism. Most studies that 
have investigated the Aβ–PrP interaction used Aβ-derived 
diffusible ligands (ADDLs) [19, 23, 31, 32, 66, 73, 84, 91, 
93], a recipe-based preparation which contains monomers, 
protofibrils and globular oligomers [39, 52, 66]. However, 
we have shown that the duration of incubation used to gener-
ate ADDLs has dramatic effects on both binding to PrP and 
neurotoxicity [66]. Specifically, we found that fibrils and 
globular oligomers bind only weakly to PrP and mediate 
toxicity in a  PrPC-independent manner. For instance, globu-
lar oligomers cause membrane leakage independent of the 
presence of PrP, and Aβ fibrils block LTP in slices from both 
wild-type (WT) and PrP-deficient mice. In contrast, soluble 
aggregates composed largely of protofibril-like structures 
block LTP in a PrP-dependent fashion [66].
Given the pleomorphic nature of Aβ assemblies formed 
in vitro [89] and those in extracts of human brain [25, 41, 
92], it is reasonable to expect that toxicity is mediated by 
more than one Aβ assembly and that this could involve 
interactions between specific Aβ assemblies and specific 
receptors, such as  PrPC and rather non-specific membrane 
perturbations [87].  PrPC is a membrane-associated protein 
best known for its role in transmissible spongiform encepha-
lopathies [71]. Since the infectious component of these dis-
eases is proteinaceous, they are also referred to as prion dis-
eases. Prions reproduce by converting helical-rich  PrPC into 
β-sheet-rich infectious  PrPSc [69]. Although initially unan-
ticipated, the finding that  PrPC can serve as a receptor for 
oligomeric forms of Aβ [53] fits well with the known ability 
of  PrPC to bind misfolded PrP [6, 16] and opens up the tan-
talizing possibility that PrP may recognize a conformation 
shared by other disease-associated protein aggregates.
Recently, several studies have imputed a role for  PrPC 
in binding to, and mediating, αSyn and tau toxicity [29, 
42, 67]. For tau, this association has been indirect, rely-
ing on certain antibodies to block  PrPC [42, 67] and in 
the case of αSyn there have been conflicting results [29, 
86]. No studies have directly compared the interaction 
of αSyn, tau and Aβ with PrP or explored the activity 
of human brain-derived αSyn and tau. Here, we set out 
to systematically explore whether certain assemblies of 
tau and αSyn can bind to PrP and whether this binding 
has disease-relevant consequences. For this purpose, we 
developed a robust protocol that allows the reproducible 
generation of soluble protein aggregates (SPAs) of Aβ, 
tau and αSyn. Thereafter, we tested binding to PrP using 
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a sensitive solid-phase ELISA-like assay, PrP deletion 
constructs, mouse primary neurons that express or lack 
PrP, iPSC-derived human neurons (iNs) with and with-
out CRISPR-mediated deletion of PRNP, and aqueous 
extracts of AD, DLB and PiD brains. Importantly, SPAs of 
tau and αSyn bound to PrP with high affinity, but (as with 
Aβ) monomers and end-stage fibrils displayed little or 
no binding. Moreover, anti-PrP antibodies to the putative 
Aβ binding Sites I and II [19, 31, 32, 62] effectively dis-
placed SPAs of αSyn and tau, and deletion of these sites 
substantially attenuated binding. Multielectrode record-
ings from hippocampal slices of PrP WT mice revealed 
that soluble aggregates (but not monomers) of Aβ, tau 
and αSyn impair LTP, and recordings from PrP null mice 
demonstrate that this impairment required expression of 
PrP. Additionally, high-content imaging and bioactivity 
assays utilizing primary mouse and iPSC-derived human 
neurons revealed that soluble aggregates of all three pro-
teins interact with PrP on neuronal surfaces and exert 
dose- and time-dependent neuritotoxicity. In contrast, 
soluble aggregates of albumin bound only weakly to PrP 
and were not toxic to neurons. Most relevant to human 
disease, knock-out of PrP and pre-treatment with anti-PrP 
antibodies prevented toxicity of brain extracts from AD, 
PiD and DLB brains. Collectively, these results suggest 
that PrP plays an important role in brain proteinopathies 




Human Aβ1–42 was synthesized and purified by Dr. James 
I. Elliott at the Yale University Keck Biotechnology 
Resource Laboratory (New Haven, CT). Peptide mass and 
purity (> 95%) was confirmed by electrospray ionization/
ion trap mass spectrometry and reverse-phase HPLC. Full-
length human α-synuclein (1–140) was kindly provided 
by Prof. Sara Linse (Lund University Center for Molecu-
lar Protein Science, Lund, Sweden) and murine  PrP91–231 
and  PrP119–231 were graciously provided by Prof. John 
Collinge (University College London MRC Prion Unit, 
London, UK). The longest isoform of human tau (2N4R; 
hTau40) and murine  PrP23–231 were purified in house and 
are detailed below. Aqueous paraformaldehyde was from 
Electron Microscopy Services (Hatfield, PA) and cell cul-
ture reagents were obtained from ThermoFisher (Carlsbad, 
CA). All other chemicals and reagents were of the highest 
purity available and were obtained from MilliporeSigma 
(St. Louis, MO) unless indicated otherwise.
Antibodies
The antibodies, their sources and epitopes are described 
in Supplementary Table 2.
Preparation of recombinant prion protein 23–231
Escherichia coli (E. coli) strain BL21(DE3)pLysS (New 
England BioLabs, Ipswich, MA) was transformed with the 
pTrcHis B vector expressing murine  PrP23–231 [32, 44, 94]. 
Ampicillin-resistant colonies were selected, expanded and 
expression was induced by the addition of 1 mM IPTG 
for 16 h at 37 °C and 225 RPM. Cultures were harvested 
by centrifugation at 6000×g for 15 min, washed in PBS 
and lysed by sonication (2 × 120 s bursts at 30% output) 
in extraction buffer (50 mM Tris–HCl, pH 8.0, 200 mM 
NaCl, 0.1% Tween-20, 50 U/mL Benzonase, 10 μg/mL 
lysozyme). Suspensions were sedimented at 10,000×g 
for 30 min and the inclusion body-enriched pellets were 
extracted by sonication (2 × 120 s bursts at 30% output) 
in solubilization buffer (6 M GuHCl/50 mM Tris–HCl 
pH 8.0/0.8% β-mercaptoethanol). Suspensions were 
sedimented at 21,000×g for 45 min and the PrP-enriched 
supernatant was clarified with 5 µM and 0.45 µM syringe 
filters. Filtered supernatants were loaded onto 5 mL His-
Trap HP columns (GE Life Sciences, Marlborough, MA) at 
1 mL/min using a BioLogic DuoFlow FPLC system (Bio-
Rad, Hercules, CA) and washed with 10 column volumes 
(CV) of Buffer A (6 M GuHCl, 10 mM Tris–HCl, 100 mM 
 Na2HPO4, 10 mM Glutathione pH 8.0) at 1 mL/min. Bound 
PrP was refolded on-column in a linear gradient of Buffer 
A to Buffer B (10 mM Tris–HCl, 100 mM  Na2HPO4, pH 
8.0) for 30 CV at 0.213 mL/min (11 ¾ h). The following 
day, the column was eluted in a linear gradient of Buffer 
B to Buffer C (10 mM Tris–HCl, 100 mM  Na2HPO4, 1 M 
imidazole, pH 5.8) for 3 CV at 0.5 mL/min and the frac-
tions containing PrP were buffer exchanged with 2 kDa 
dialysis cassettes (ThermoFisher, Waltham, MA) overnight 
at against 1000 volumes of 20 mM Bis–Tris HCl, pH 6.5. 
The poly-histidine tag was cleaved from PrP using 50 U 
restriction-grade thrombin (Novagen, Madison, WI) over-
night with agitation, and cleaved PrP was separated from 
the free histidine tag using a 5-mL HisTrap HP column. 
The fractions containing purified PrP were dialyzed over-
night against 1000 volumes of 10 mM Bis–Tris HCl, pH 
6.5. Protein purity was determined by SDS-PAGE/sliver 
staining and mass spectrometry, and secondary structure 
was analyzed by circular dichroism (Jasco J-815, Jasco, 
Easton, MD). Concentration was determined by measuring 
absorbance at 280 nm and using the predicted extinction 




Secondary structure of PrP fragments was determined using 
a Jasco J-815 circular dichroism (CD) spectropolarimeter 
(Jasco Inc., Easton, MD). Proteins were buffer exchanged 
into 10 mM phosphate buffer, pH 7.4 using Zeba Micro-
Spin Desalting Columns (ThermoFisher, Waltham, MA) and 
diluted to 0.2 mg/mL for analysis. Near-UV signals were 
obtained by scanning from 260 to 180 nm at 50 nm/min 
with 2 s data integration time and 5 toggled accumulations. 
Each sample was measured in triplicate, and high tensor 
voltage never eclipsed 700 units across all measurements. 
Mean residue ellipticity was calculated from raw CD signals 
using the formula [θ] = 100(signal)
Cnl
 , where [θ] = mean residue 
ellipticity in deg  cm2  dmol−1; signal = raw output in mdeg; 
C = protein concentration in mM; n = number of residues; 
l = path length in cm [64].
Preparation of recombinant Tau441 (hTau40)
Expression and purification of tau was performed essen-
tially as described [47, 68]. E. coli strain BL21 (DE3) (New 
England BioLabs, Ipswich, MA) was transformed with a 
pNG2 vector encoding human tau 441 (2N4R) and protein 
expressed by the addition of 1 mM IPTG for 4 h at 37 °C and 
225 RPM. After cell lysis, the soluble fraction containing 
tau was separated from insoluble material by boiling and 
ultracentrifugation, and tau was purified by anion exchange 
followed by two-step size exclusion chromatography. Purity 
of the proteins was assessed by SDS-PAGE/sliver staining 
and mass spectrometry. Concentration was determined by 
measuring absorbance at 280 nm and using the predicted 
extinction coefficient (ε280 = 7575 M−1 cm−1).
Aggregation of Aβ, α‑synuclein and tau
Aβ
One milligram lyophilisates were dispersed in denaturant 1 
(7 M GuHCl and 5 mM EDTA), incubated overnight at room 
temperature, and monomer isolated by size exclusion chro-
matography (SEC) on a Superdex 75 10/300 column eluted 
with Aβ buffer (20 mM  NaPO4, 0.2 mM EDTA, 0.02%  NaN3, 
pH 8.0). Only the peak fractions were retained for aggrega-
tion assays. Aggregation was monitored using a continuous 
thioflavin-T (ThT) fluorescence assay performed essen-
tially as described [38]. SEC-isolated peptide was diluted 
to 20.1 μM with Aβ buffer and combined with ThT to yield 
30 μM ThT and 20 μM Aβ. Six replicates (100 μl) were trans-
ferred to wells of black, clear bottom, half-area PEG-ylated 
96-well plates (#3881; Corning Life Sciences, Corning, NY). 
Reactions prepared in the absence of ThT were used for 
downstream fibril harvest, and blanks without any Aβ were 
included. Plates were covered with adhesive plate sealers 
(VWR, Radnor, PA) and incubated at 37 °C in a POLARstar 
Omega plate reader (BMG Labtech, Ortenberg, Germany). 
Fluorescence was recorded every 5 min  (Ex440 and  Em480) 
and reactions were carried out for at least 15 h.
α‑Synuclein
Three-milligram lyophilisates were dispersed in denaturant 2 
(6 M GuHCl, 25 mM Tris and 5 mM EDTA), incubated for 
2 h at room temperature and chromatographed on a Superdex 
75 10/300 column eluted with αSyn buffer (10 mM MES, 
140 mM NaCl, pH 5.5). As with Aβ, only the peak frac-
tions were retained for aggregation assays. Aggregation was 
monitored using a continuous ThT assay [35], with modi-
fication. SEC-isolated peptide was diluted to 40 μM with 
αSyn buffer and combined with ThT to yield 20 μM ThT 
and 35 μM αSyn. Six replicates (100 μL) were transferred 
to wells of black, clear bottom, full-area nontreated 96-well 
plates (#3631; Corning Life Sciences, Corning, NY). Reac-
tions prepared in the absence of ThT were used for down-
stream fibril harvest, and blanks without any αSyn were 
included. Plates were covered with adhesive plate sealers 
(VWR, Radnor, PA) and incubated at 37 °C in a POLARstar 
Omega plate reader (BMG Labtech, Ortenberg, Germany) 
with shaking at 100 RPM for 300 s before each reading. 
Fluorescence was recorded every 10 min  (Ex440 and  Em480) 
and initial reactions were carried out for at least 96 h.
Tau
Monomeric tau was isolated by SEC using a Superdex 
75 10/300 column eluted with tau buffer (138 mM NaCl, 
2.7 mM KCl, 5 mM 1,4-dithiothreitol (DTT)) to reduce 
cysteine-mediated dimerization. As with Aβ and αSyn, 
only the peak fractions were retained for aggregation assays. 
Approximately 3–5 mg of tau in solution was concentrated 
to ≥ 60 µM using 10 kDa Amicon centrifugal filters (Mil-
liporeSigma, St. Louis, MO) and buffer exchanged into 
50 mM MES, pH 6.5 using 7 kDa Zeba desalting columns 
(ThermoFisher, Waltham, MA). Tau was diluted to 58.8 µM 
with 50 mM MES, pH 6.5, mixed with a 10X stock of DTT 
and heated at 55 °C for 10 min in protein lo-bind tubes 
(Eppendorf, Hamburg, Germany). Thereafter, the mixture 
was cooled to room temperature and heparin (#H4784; Mil-
liporeSigma, St. Louis, MO) was added from a 20X stock so 
that the final aggregation reaction (in 250 µL) was: 50 µM 
tau, 100 µM DTT, 50 µM heparin. Tubes were incubated 
in a thermomixer (600 RPM) set to 37 °C and incubated 
for up to 12 days. Every third day, 10 µL aliquots from the 
aggregation reactions were removed and aggregation moni-
tored by discontinuous ThT assay. Samples were diluted to 
10 µM with MilliQ, supplemented with 10 µL 200 µM ThT 
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and transferred to wells of black, clear bottom, half-area 
PEG-ylated 96-well plates (#3881; Corning Life Sciences, 
Corning, NY). Plates were incubated for 45 min with shak-
ing at 300 RPM, and ThT fluorescence  (Ex440 and  Em480) 
was measured with a POLARstar Omega plate reader (BMG 
Labtech, Ortenberg, Germany).
Generation and quantification of soluble protein 
aggregates
The procedure used to produce soluble aggregates of Aβ, 
α-synuclein and tau from fibrils was identical for each pro-
tein. End stage fibrils were pelleted by ultracentrifugation at 
100,000×g for 1 h, and 90% of the supernatant was removed 
and retained for measurement by ELISA. The pellet was 
washed twice by resuspension in sterile PBS and centrifu-
gation at 100,000×g for 1 h, and the final pellet was resus-
pended in sterile PBS. One-quarter of the washed fibrils 
were retained as fibril stocks, and the other three-quarters 
were immersion sonicated at 10 kHz for 10 × 5 s bursts with 
15-s rests between bursts. Thereafter, the sonicated mate-
rial was centrifuged at 16,000×g and 4 °C for 10 min, and 
90% of the soluble supernatant was collected, aliquoted and 
stored frozen at – 80 °C until use.
Since SPAs scatter light and may not bind BCA uniformly 
it is not possible to use conventional assays to determine 
protein concentrations. Instead, we used ELISAs to measure 
the starting monomer concentration and the amount of mon-
omer left in solution after sedimenting fibrils. We then used 
these values to calculate the per cent monomer incorporated 
into fibrils and hence, the molar amount of protein in fibrils, 
i.e. 100 −
(




 . Across 
three independent experiments, we found that ~ 98% of start-
ing Aβ was incorporated into fibrils, whereas ~ 78% of αSyn 
and ~ 77% of tau were incorporated into fibrils. Using this 
information, we estimated the molar concentration of the 
resulting SPA preparations.
Sedimentation‑ThT assays
To monitor ThT binding of fractions produced through the 
soluble aggregate generation process, portions of samples 
produced at each step were retained for end-point ThT 
assays. These fractions were: B, aggregation buffer alone; 
M, freshly prepared monomeric protein; N, neat end-stage 
fibrillary material; S, high-speed supernatants obtained after 
pelleting fibrils; P, high-speed fibril pellet; and sonicated 
soluble material. Protein concentrations and ratios to ThT 
were identical to the continuous or end-point assays used for 
each protein’s primary aggregation reactions.
Solid‑phase PrP binding assays
Three separate microtiter assays were employed: (i) an 
indirect ELISA to quantify binding of anti-PrP mAbs to 
recombinant PrP, (ii) a modified indirect ELISA to measure 
binding of forms of Aβ, α-synuclein, tau and BSA to recom-
binant PrP and (iii) a displacement ELISA to measure mAb-
mediated inhibition of protein binding to PrP. The same 
clear, half-area, high-binding microtiter plates (#675061; 
Greiner Bio-One, Monroe, NC) were used for all assays, and 
 EC50/IC50s were calculated using GraphPad Prism 7.1. All 
plates were developed with 50 µL/well 3,3′,5,5′-Tetrameth-
ylbenzidine (TMB; ThermoFisher, Waltham, MA), stopped 
by the addition of 50 µL/well 1 M  H2SO4 and read at 450 nm 
using a SpectraMax plate reader (Molecular Devices, Sun-
nyvale, CA). For dilutions of antibodies used, please see 
Supplementary Table 2.
Antibody binding ELISAs
Plates were coated with 30 µL/well of 0.5 µM  PrP23–231, 
 PrP91–231, or  PrP119–231 and incubated for 1 h at 37 °C and 
300 RPM. Plates were washed three times with 100 µL/well 
PBS + 0.05% Tween-20 (PBST) and blocked with 100 µL/
well of 2% BSA at room temperature (RT) for 2 h and 300 
RPM. Plates were washed three times with 100 µL/well 
PBST before 30 µL/well of different anti-PrP mAbs diluted 
in PBST + 0.5% BSA were added to the plates and incubated 
at RT for 1 h and 300 RPM. Plates were again washed three 
times with 100 µL/well PBST and 30 µL/well horseradish 
peroxidase (HRP)-conjugated secondary antibodies (diluted 
1:15,000 in PBST + 1% BSA) were added and incubated at 
RT for 1 h and 300 RPM. After 3 × 100 µL/well washes with 
PBST, plates were developed.
PrP‑binding ELISAs
Plates were coated with 30 µL/well of 0.5 µM  PrP23–231, 
 PrP91–231, or  PrP119–231 and incubated for 1 h at 37 °C and 
300 RPM. Plates were washed three times with 100 µL/well 
PBS + 0.05% Tween-20 (PBST) and blocked with 100 µL/
well of SuperBlock PBS (ThermoFisher, Waltham, MA) at 
room temperature (RT) for 2 h and 300 RPM. Plates were 
washed three times with 100 µL/well PBST before 30 µL/
well of different proteins diluted in PBST + 0.5% BSA were 
added to the plates and incubated at RT for 1 h and 300 
RPM. Plates were washed, and bound Aβ, αSyn, tau were 
detected with 30 µL/well 3D6, 2F12 and HJ8.5, respectively, 
diluted in PBST + 0.5% BSA at RT for 1 h and 300 RPM. 
Thereafter, bound antibodies were detected with 30 µL/
well horseradish peroxidase (HRP)-conjugated secondary 
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antibodies (diluted 1:15,000 in PBST + 1% BSA) at RT for 
1 h and 300 RPM. After 5 × 100 µL/well washes with PBST, 
plates were developed.
Displacement ELISAs
Plates were coated with 30 µL/well of 0.5 µM  PrP23–231 
and incubated for 1 h at 37 °C and 300 RPM. Plates were 
washed three times with 100 µL/well PBS + 0.05% Tween-
20 (PBST) and blocked with 100 µL/well of SuperBlock 
PBS (ThermoFisher, Waltham, MA) at room temperature 
(RT) for 2 h and 300 RPM. Plates were washed three times 
with 100 µL/well PBST before 30 µL/well of different anti-
PrP mAbs diluted in PBST + 0.5% BSA were added to the 
plates and incubated at RT for 1 h and 300 RPM. After 
washing, plates were incubated with 156 nM Aβ, αSyn or 
tau and incubated at RT for 1 h and 300 RPM, washed, and 
bound Aβ, αSyn or tau detected with HRP-conjugated 3D6, 
2F12 and HJ8.5, respectively, diluted in PBST + 0.5% BSA 
at RT for 1 h and 300 RPM. Thereafter, bound antibodies 
were detected with 30 µL/ well of streptavidin-HRP (R&D 
Systems, Minneapolis, MN) diluted 1:200 in PBST + 0.5% 
BSA at RT for 1 h and 300 RPM. After 5 × 100 µL/well 
washes with PBST, plates were developed.
Negative contrast electron microscopy 
and quantification
Samples were stained and visualized essentially as described 
previously [10, 90]. Aliquots of freshly thawed protein sam-
ples were adsorbed (10 μl) neat onto formvar-coated cop-
per grids (Electron Microscopy Sciences, Hatfield, PA) for 
1 min before 10 μl of 0.25% glutaraldehyde (ThermoFisher, 
Waltham, MA) was added and incubated for 1 min. There-
after, grids were wicked dry using qualitative filter paper 
(VWR, Radnor, PA), washed twice with 10 μl MilliQ water 
and then stained with 1% uranyl acetate for 2 min. Grids 
were wicked dry as above and allowed to air dry for at least 
10 min, stored at room temperature and then examined using 
a 1200EX microscope (JEOL).
For measurement of soluble protein aggregates, at least 
three grids per protein were mounted, and at least three 
images per protein were analyzed. Length, defined as the 
long axis of each fragment measured, was measured using 
FIJI [77] and binned into 8 nm segments [66] using the scale 
bar as a standard (2.58 pixels/nm). Particles were excluded 
from analysis if they were on the border of the image or 
did not have clearly defined edges (i.e. due to a clustering). 
All particles meeting these criteria within the image field of 
view were also analyzed for width, defined as the short axis 
of each measured fragment.
Animals
All procedures were performed in accordance with the 
National Institutes of Health Policy on the Use of Animals in 
Research and were approved by the Harvard Medical School 
Standing Committee on Animals. Founder Prnp−/− mice 
[13] were from DAH’s colony. Single nucleotide polymor-
phism genotype scanning indicated Prnp−/− mice were on a 
background of 98.13% C57BL/6J (The Jackson Laboratory, 
Bar Harbor, ME). Prior to expansion of the DMW colony 
Prnp−/− mice were back-crossed with C57BL/6J mice (The 
Jackson Laboratory, Bar Harbor, ME) to generate hemizy-
gotes that were then interbred to create wild-type (WT) and 
Prnp−/− littermates. For each experiment, mice were geno-
typed by PCR before use. Animals were housed in a room 
with a 12 h light/dark circadian cycle with ad libitum access 
to food and water.
Mouse primary neuronal cultures
Primary neurons were prepared as described previously [46], 
with modification. All media and solutions were 0.22 µm 
sterile filtered. Cortices were explanted from embryonic day 
15–18 pups in ice-cold Dissection Buffer A (DSA: Phenol 
red-free HBSS with  Ca2+ and  Mg2+, 1 mM sodium pyruvate, 
10 mM HEPES, pH 7.4). Tissue was transferred to ice-cold 
Dissection Buffer B (DSB: HBSS without  Ca2+ and  Mg2+, 
1 mM sodium pyruvate, 10 mM HEPES, pH 7.4), carefully 
washed three times and microdissected free of meninges. 
Thereafter, cortices were partially dissociated in warm DSB 
with 0.125% trypsin–EDTA for 16 min at room tempera-
ture with gentle inversion every 4 min. Cortices were then 
rinsed three times in warm Neurobasal medium (NBM: 
Neurobasal, 1X GlutaMax-I, 1X B27 supplement). Com-
plete dissociation was performed manually using a series 
of increasingly smaller pipette tips (1 mL tip, 200 μl tip, 
followed by a series of fire polished glass pipettes) followed 
by an incubation period of 15 min at 37 °C. Suspensions 
were strained through a 40-μM nylon cell strainer (Corn-
ing Life Sciences, Corning, NY) and intact cells separated 
from debris by centrifugation at 200 × g for 5 min. Cell 
pellets were resuspended in NBM, counted using a trypan 
blue-based automated cell counter (Bio-Rad, Hercules, CA) 
and plated on poly-l-lysine coated plates (MilliporeSigma, 
St. Louis, MO) at densities of 1 × 104 or 1 × 106 cells/well 
in 96-well and 6-well plates, respectively. Four days after 
plating, half the media was replaced with NBM containing 
10 μm 5-fluoro-2′-deoxyuridine (MilliporeSigma, St. Louis, 
MO) to reduce proliferation of dividing cells. Cultures were 
kept in a humidified incubator at 37 °C with 5%  CO2 and 
were supplemented once per week with fresh NBM. Neurons 




Two- to three-month-old male and female animals were 
deeply anesthetized with isoflurane and decapitated. 
Brains were excised and immediately immersed in ice-cold 
(0–4 °C) artificial cerebrospinal fluid (aCSF) comprised of 
(in mM): 124 NaCl, 3 KCl, 2.4  CaCl2, 2  MgSO4·7H2O, 1.25 
 NaH2PO4, 26  NaHCO3 and 10 d-glucose and was equili-
brated with 95%  O2 and 5%  CO2, pH 7.4, 310 mOsm. Coro-
nal brain slices (300 µm), including hippocampus were pre-
pared using a Leica VT1000 S vibratome (Leica Biosystems 
Inc, Buffalo Grove, IL), transferred to an interface chamber 
and incubated at 34 ± 5 °C for 20 min, then kept at room 
temperature for 1 h before recording [90].
Microelectrode array measurement of long‑term 
potentiation (LTP)
A medium-throughput 64-channel MED64-Quad II system 
(Alpha MED Scientific, Osaka, Japan) was used for extra-
cellular field potential recordings. Before each experiment, 
the surface of the MED64-Quad II probe was treated with 
0.7 mL 0.1% polyethyleneimine (PEI) in 25 mM borate 
buffer (pH 8.4) overnight at room temperature. The follow-
ing day, PEI was aspirated, the probe was rinsed with dis-
tilled water 4 times, covered with 1 mL distilled water and 
stored at 4 °C until use. Thereafter, brain slices were trans-
ferred to the MED probe 16 (2 × 8) and the electrodes were 
positioned in the stratum radiatum of CA1 under the guid-
ance of inverted phase contrast microscope (Nikon TMS-F, 
Nikon Instruments Inc, Melville, NY). Reference images 
were taken by ISCapture using a digital camera (AmScope) 
connected to the microscope. Once the slice settled, a fine-
mesh and a slice anchor (Warner Instruments, Harvard 
Bioscience Inc.) were carefully positioned to ensure slice 
stabilization during recording. The MED probe was then 
inserted into the MED connector (MED64 ThermoBase II, 
MED-CPB02) and a perfusion cap was used to circulate 
oxygenated aCSF (maintained at 30 °C) into the probe and 
prevent the slices from drying. Perfusion was controlled by 
a MED64 pump (input rate of 1.6 mL/min) while humidi-
fied oxygen entered the probe at 0.5 L/min. A total of four 
brain slices per experiment were placed on the 4 MED16 
probes and, after 10 min of recovery, 1 of 16 (2 × 8) planar 
microelectrodes was selected as the stimulation electrode. 
Field excitatory postsynaptic potentials (fEPSPs) were 
evoked by a monopolar, biphasic constant current pulse 
(0.2 ms in duration) generated by the data acquisition soft-
ware (Mobius, Alpha-Med Scientific). The electrode along 
the Schaffer collaterals with the best fEPSPs was chosen as 
recording electrode. Next, the input–output (I/O) curve was 
measured and the baseline stimulation intensity was set to 
40% of maximum fEPSPs slope. During baseline recording, 
stimuli were delivered to 4 slices with 5-s intervals. After 
30 min, LTP was induced by theta burst stimulation (TBS, 
10 bursts at 5 Hz, 4 pulses at 100 Hz for each burst) three 
times with 4.25-s intervals. After TBS, the baseline stimu-
lus was given to four slices repeatedly with 5-s intervals for 
another hour. Signals were amplified by the MED64 Main 
Amplifier (MED-A64MD1A) and MED64 Head Ampli-
fier (MED-A64HE1S), then digitized at a 10-kHz sampling 
rate. The digitized data were exported for offline analysis. 
Within each measurement, one slice was used for aCSF con-
trol while the other three slices were treated with different 
concentration of SPAs. Each set of four slices were from a 
single animal and between three and five animals were used 
for each SPA experiment.
Immunocytochemistry and quantification
Mouse primary neurons (MPNs) and induced neurons (iNs) 
seeded in clear bottom, black wall 96-well plates (#655090; 
Greiner Bio-One, Monroe, NC) were immunostained using 
a modified serial-permeabilized protocol [33]. All buffers 
and reagents were prepared fresh and 0.22 µm filtered prior 
to use. Cells were washed three times with warm aCSF and 
fixed with ice-cold 4% paraformaldehyde/4% sucrose in PBS 
for 10 min at 4 °C. Thereafter, plates were washed once 
with PBS, quenched with 0.1 M glycine in PBS for 10 min 
at room temperature, washed three times with PBS and 
stored at 4 °C overnight. After fixing, all subsequent steps 
were performed on a shaker set to speed ‘2’. The following 
day, plates were warmed to room temperature for 30 min 
and processed one of two ways: (i) for total cellular stain-
ing, cells were permeabilized with 0.25% Triton X-100 in 
PBS for 5 min prior to blocking, or (ii) for surface staining, 
cells were immediately blocked without the permeabiliza-
tion step. Blocking was done with 3% BSA in PBS for 2 h 
before plates were washed three times with PBS and incu-
bated for 2 h with primary antibodies (see Supplementary 
Table 2 for antibodies and dilutions) diluted in 3% BSA/
PBS. Thereafter, plates were washed 6 × 5 min with 0.05% 
PBST, and plates that had not been previously permeabilized 
were treated with 0.25% Triton X-100 in PBS for 5 min to 
unmask intracellular epitopes, incubated with primary anti-
bodies (as above) against structural markers (Supplementary 
Table 2) and washed 6 × 5 min with 0.05% PBST. Bound 
antibodies were detected by the addition of the appropri-
ate Alexa Fluor conjugated secondary antibodies (diluted 
1:500 in 3% PBST/BSA; ThermoFisher, Waltham, MA) for 
1 hour and plates were washed 6 × 5 min with 0.05% PBST, 
incubated for 5 min with DAPI (1 µg/mL; ThermoFisher, 
Waltham, MA) in PBS, washed a further three times with 
PBS and imaged using a GE InCell 2200. The acquisition 
settings were as follows: objective, Nikon 20X/0.45 Pan-
Fluorescent CFI/60; channels, DAPI, FITC_511, Cy3, Cy5; 
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binning, 1 × 1; polychroic, QUAD1; laser autofocus, 10%. 
All images were flat-field corrected with 2-D deconvolution, 
and quantification of puncta was performed using a custom, 
automated FIJI macro.
On‑cell western blot
Binding of soluble aggregates to MPNs was analyzed using 
a modified on-cell Western blot protocol. All buffers and 
reagents were prepared fresh and 0.22 µm filtered prior to 
use and infrared dye-compatible reagents were from LI-COR 
Biosciences (Lincoln, NE). On DIV 20–22, cells seeded 
at 1 × 104 cells/well in 96-well clear bottom, black wall 
96-well plates (#655090; Greiner Bio-One, Monroe, NC) 
were treated with soluble protein aggregates for 2 h at 37 °C. 
Cells were washed three times with warm aCSF and fixed 
with ice-cold 4% paraformaldehyde/4% sucrose in PBS for 
10 min at 4 °C. Thereafter, plates were washed once with 
PBS, quenched with 0.1 M glycine in PBS for 10 min at 
room temperature, washed three times with PBS and stored 
at 4 °C overnight. After fixing, all subsequent steps were 
performed on a shaker set to speed ‘2’. The following day, 
plates were warmed to room temperature for 30 min and 
blocked in 100 µL/well LI-COR Blocking Buffer for 2 h at 
RT. Thereafter, primary antibodies to surface antigens were 
diluted in LI-COR Blocking buffer and incubated for 2 h at 
RT. Cells were then washed with PBS, permeabilized by 
the addition of with 0.25% Triton X-100 in PBS for 5 min, 
incubated with primary antibodies against structural markers 
(Supplementary Table 2) and washed 6 × 5 min with 0.05% 
PBST. IR-labeled secondary antibodies (diluted 1:1000 in 
LI-COR Blocking Buffer + 0.1% Tween-20) were added for 
1 h at RT before plates were washed extensively with PBST 
and imaged using a LI-COR Odyssey CLx infrared imaging 
system.
SDS‑PAGE, coomassie staining and western blotting
Mouse primary neurons and iNs were seeded in 6-well-
plates at 1 × 106 or 5 × 105 cells/well, respectively, washed 
twice with warm aCSF, scraped into 1% CHAPS lysis buffer 
(1% CHAPS, 30 mM Tris–HCl, 150 mM NaCl pH 7.5 + pro-
tease and phosphatase inhibitors) and incubated on ice for 
10 min. Suspensions were homogenized on ice with 20 
strokes of a motorized Teflon pestle (Argos Technologies, 
Vernon Hills, IL), freeze-thawed once, incubated a further 
10 min on ice and centrifuged 10,000×g for 15 min. Post-
nuclear supernatants were retained and protein concentra-
tions determined by  A280 (NanoDrop 2000, ThermoFisher, 
Waltham, MA). Ten to thirty µg lysate or 0.25 to 1 µg recom-
binant/synthetic protein was mixed with 4X LDS-phenol red 
sample buffer, boiled and electrophoresed on 17- or 26-well 
precast 4–12% Bis–Tris gels (ThermoFisher, Waltham, MA). 
For Coomassie staining of purified proteins, gels were rinsed 
briefly with MilliQ, fixed in 50% methanol, 10% glacial ace-
tic acid, washed 2 × 5 min in MilliQ and stained with Gel-
Code Blue (ThermoFisher, Waltham, MA) for 1 h at room 
temperature. Gels were destained with frequent washes in 
MilliQ and imaged using a LI-COR Odyssey CLx infrared 
imaging system (all LI-COR, Lincoln, NE). For Western 
blotting, proteins were transferred onto 0.2 µm nitrocellulose 
at 400 mA and 4 °C for 2 h, and total protein was visualized 
by REVERT stain. Membranes were then blocked for 1 h 
with Odyssey Blocking Buffer, incubated with primary anti-
bodies (Supplementary Table 2) overnight at 4 °C, washed 
6 × 10 min with PBST, incubated with IR-dye conjugated 
secondary antibodies (1:17,000), washed 6 × 5 min with 
PBST and bands were visualized using a LI-COR Odyssey 
CLx infrared imaging system (all LI-COR, Lincoln, NE). In 
some cases, densitometry was performed using FIJI (Sup-
plementary Figure 4) by normalizing the optical densities of 
PrP, tau and β-III-tubulin bands to those for GAPDH [77].
Production of induced neurons (iNs) from human 
induced pluripotent cells (iPSCs)
The YZ1 iPSC line [95] was used to prepare neurogenin 
2 (Ngn2)-induced human neurons [96] as described previ-
ously [41, 45]. On iN day 4, cells were plated at 4000 cells/
well on Matrigel (Corning Life Sciences, Corning, NY)-
coated plates (#655090; Greiner Bio-One, Monroe, NC) and 
maintained until iN day 21, a time point when iNs are fully 
mature (Supplementary Figure 5A).
CRISPR iPSC editing
Single guide RNA (sgRNA) sequences were designed as pre-
viously reported [76] and cloned into the pXPR_003 plasmid 
(Addgene #52963) by PCR. Healthy control YZ1.4 iPSCs 
(1 × 105) were plated on growth factor-reduced Matrigel 
(Corning Life Sciences, Corning, NY) and cultured in Stem-
Flex medium. The following day, cells were co-transfected 
with SpCas9 (pXPR_BRD111Cas9v2; Addgene #78166) 
and PRNP sgRNA or empty plasmids using Lipofectamine 
2000 (ThermoFisher, Waltham, MA). Two days post-trans-
fection, iPSCs were selected with puromycin (5 µg/mL) 
and blasticidin (4 µg/mL). Thereafter, genomic DNA was 
extracted from a subset of cells and editing was monitored 
by mismatch assay (GeneArt Genomic Cleavage Detection 
Kit, ThermoFisher, Waltham, MA). Limited dilution sub-
cloning was used to isolate edited iPSCs, and monoclonal 
lines were examined by PCR-sequencing around the edited 
region. Hit clones were expanded, differentiated into iNs and 
cultured until iN D21, at which point cells were harvested 




RNA was extracted from iPSCs and iNs with TRIzol, 
reverse-transcribed and complementary DNA (cDNA) 
was used for quantitative real-time PCR (qPCR) using Fast 
SYBR Green Master Mix on a ViiA 7 system (all Ther-
moFisher, Waltham, MA). Data were normalized to glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) expression 
using the ΔΔCT method [56].
Live‑cell imaging and neuritotoxicity assays
On iN DIV21 or when primary mouse neurons were 20–22 
DIV, plates were transferred to an IncuCyte Zoom live-cell 
imaging instrument (Essen Bioscience, Ann Arbor, MI) and 
images collected every 2 h for a total of 6 h. These three 
image sets were used to establish ‘before treatment’ baseline 
neurite length measurements. Immediately thereafter, ¾ the 
culture medium was removed (leaving ~ 50 µL) and recom-
binant protein preparations were diluted into 50 µL fresh 
NBM and added to cells (three technical replicates per pro-
tein per plate, three experimental replicates in total). When 
human brain extracts were tested, ½ the culture medium was 
removed (leaving ~ 100 µL) and 25 µL desalted extracts (see 
‘Preparation of Human Brain Extracts’ below) were diluted 
with 75 µL fresh NBM and added to cells. Phase-contrast 
images were collected from four fields per well every 2 h 
(for a total of 96 h) and analyzed using the IncuCyte Zoom 
2016A NeuroTrack analysis platform (Essen Bioscience, 
Ann Arbor, MI) to define neurites and somas. Total neurite 
length (in mm) was quantified and normalized to the aver-
age value measured during the 6-h period prior to sample 
addition.
Preparation of human brain extracts
Human specimens used for biochemical experiments were 
obtained from the Massachusetts ADRC Neuropathology 
Core, Massachusetts General Hospital and used in accord-
ance with the Partners Institutional Review Board (Protocol: 
Walsh BWH 2011). Frozen cortical tissues were obtained 
from seven cases, two each who died with AD, DLB and 
FTD and one individual who died free of any signs of neu-
rodegeneration (Supplementary Table 1). All diseased cases 
met current post-mortem and clinical diagnostic criteria 
for the relevant disorder. Aqueous extracts were prepared 
as described previously [41]. Briefly, grey matter was dis-
sected free of white matter/vasculature and homogenized in 
five volumes of ice-cold base artificial cerebrospinal fluid 
(aCSF-B; 124 mM NaCl, 2.8 mM KCl, 1.25 mM  NaH2PO4, 
26 mM  NaHCO3, pH 7.4) plus protease inhibitors (5 mM 
ethylenediaminetetraacetic acid (EDTA), 1 mM ethyleneg-
lycoltetraacetic acid (EGTA), 5 μg/mL leupeptin, 5 μg/mL 
aprotinin, 2 μg/mL pepstatin, 120 μg/mL Pefabloc and 5 mM 
NaF) with 25 strokes of a mechanical Teflon-glass Dounce 
homogenizer (Fisher, Ottawa, Canada). Resulting homoge-
nates (20% w/v) were centrifuged at 200,000×g and 4 °C 
for 110 min in a SW41 Ti rotor (Beckman Coulter, Fuller-
ton, CA). The upper 80% of the supernatant was removed 
and dialyzed against 100-fold excess of fresh aCSF-B at 
4 °C using 2 kDa MWCO Slide-A-Lyzer cassettes (Ther-
moFisher, Waltham, MA). Buffer was changed three times 
over a 72-h period before dialyzed extracts were aliquoted 
and stored at – 80 °C until use.
Solid‑phase sandwich immunoassays
Aβx-42 MSD Assays: Analysis of Aβ in soluble brain extracts 
and in supernatants from end-stage Aβ1–42 fibril harvests 
were performed using monomer-preferring Aβx−42 immu-
noassays [60] employing m266 for capture and biotinylated 
21F12 for detection (Supplementary Table 2). Assays were 
performed using the Meso Scale Discovery (MSD, Rock-
ville, MD) platform and a Sector imager to analyze plates. 
The lower limit of quantitation (LLoQ), determined by 
calculating the average + 9 standard errors and 100 ± 20% 
recovery for each standard, was 39.06 pg/mL.
Tau enzyme‑linked immunosorbent assays (ELISAs)
Analysis of tau in soluble brain extracts was performed using 
a mid-region ELISA (BT2 as capture, Tau5 for detection), 
while tau in supernatants from end stage fibril harvests 
was measured using an N-terminal ELISA (Tau12 as cap-
ture, Tau5 for detection). Assays were performed exactly 
as described [37, 42] and details regarding the antibodies 
employed are listed in Supplementary Table 2. Standard 
curves were fitted to a five-parameter logistic function with 
1/Y2 relative weighting using MasterPlex Software (Mirai-
Bio). LLoQs were calculated as described for the MSD 
assays and were 31.25 pg/mL and 15.625 pg/mL for mid-
region and N-terminal assays, respectively.
α‑synuclein ELISA
α-synuclein was measured in soluble brain extracts and in 
supernatants from end stage fibril harvests using a C-ter-
minal-directed assay. Black half-area, high-binding plates 
(#655090; Greiner Bio-One, Monroe, NC) were coated with 
7 µg/mL SOY1 in TBS for 1 h at 37 °C and 300 RPM. Plates 
were then washed three times with 100 µL TBS + 0.05% 
Tween-20 (TBST) prior to blocking in 100 µL TBS contain-
ing 3% BSA for 2 h at RT and 300 RPM. Plates were washed 
three times with 100 µL TBST before 25 µL samples (diluted 
1:500 for brain extracts and 1:400 k for fibril supernatants 
in TBS containing 1% BSA) and standards were applied in 
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triplicate and agitated for 16 h at 4 °C. Next, 25 µL alkaline 
phosphatase conjugated 2F12 (diluted 1:250 in TBST con-
taining 1% BSA) was added directly to the plates without 
washing and incubated for 1 h at RT and 300 rpm. Finally, 
plates were washed three times with 100 µL TBST before 
50 µL Tropix Sapphire II (Applied Biosystems) detection 
reagent was added and incubated for 30 min at RT and 300 
RPM. Standard curves were fitted as described for the tau 
ELISAs LLoQs (62.5 pg/mL) were calculated as described 
for both the Aβ MSD and tau assays.
Immunoprecipitation/western blotting from human 
brain extracts
Aβ
Freshly thawed extracts (1 mL) from brain AD1 were pre-
cleared of nonspecific IgG with 15 μl protein A sepharose 
(PAS) beads for 1 h at 4 °C. PAS beads were sedimented 
(4000 × g for 5 min) and the supernatant divided into 0.5 mL 
aliquots. Each aliquot was incubated with 10 µL of AW7 
(Supplementary Table 2) or preimmune serum (PIS; nega-
tive control) and 15 μl PAS beads overnight at 4 °C with 
agitation. Complexes were collected by centrifugation and 
washed as previously described [90]. To effectively deplete 
Aβ, extracts were subjected to three serial rounds of IP and 
a final PAS IP alone to remove unbound IgG. The immuno-
precipitated (IP’d) Aβ was eluted by boiling in 15 μl of 2X 
sample buffer (50 mM Tris, 2% w/v SDS, 12% v/v glycerol 
with 0.01% phenol red) and electrophoresed on hand poured, 
15-well 16% polyacrylamide tris–tricine gels. Synthetic 
Aβ1–42 was included as a loading control and protein trans-
ferred onto 0.2 µm nitrocellulose at 400 mA and 4 °C for 
2 h. Blots were microwaved in PBS and Aβ detected using 
the anti-Aβ40 and anti-Aβ42 antibodies, 2G3 and 21F12, 
and bands visualized using a Li-COR Odyssey CLx infrared 
imaging system (Li-COR, Lincoln, NE).
α‑synuclein
Aqueous brain extract was depleted of α-synuclein using 
the antibody 2F12 (Supplementary Fig. 9). Freshly thawed 
extract (1 mL) from DLB1 was first pre-cleared of non-
specific IgG with 20 μl protein G agarose (PGA; Roche 
Life Sciences, Madison, WI) beads for 1 h at 4 °C. PGA 
beads were removed by centrifugation (4000×g for 5 min), 
the supernatant transferred to fresh tubes and incubated 
with 100 µg/mL 2F12 or 46–4 (isotype control, Supple-
mentary Table 2) overnight at 4 °C with agitation. The 
following day, 2 mL 2F12- or 46–4-coupled brain extracts 
were manually injected over 1 mL HiTrap Protein G HP 
columns (GE Life Sciences, Marlborough, MA) that had 
been equilibrated with 10 CV aCSF-B. Half-millilitre frac-
tions were collected from the flow through (ID fraction), 
protein concentrations were measured using bicinchionic 
acid (BCA) assays (ThermoFisher, Waltham, MA) and 
the four peak fractions (#3–6) pooled. Then, using a peri-
staltic pump, columns were washed with 20 CV aCSF-B 
before bound antibody-antigen complexes were eluted in 5 
CV 0.1 M glycine, pH 2.7. Again, half-millilitre fractions 
were collected from the elution (IP fraction) and imme-
diately neutralized with 40 µL 1 M Tris (unbuffered; pH 
10–11). Protein concentrations from the IP fraction were 
determined by  A280 (NanoDrop 2000, ThermoFisher, 
Waltham, MA), and the peak fraction (#3) was buffer-
exchanged into 50 mM  (NH4)HCO3, pH 8.5 using 7 kDa 
Zeba desalting columns (ThermoFisher, Waltham, MA). 
Samples were then lyophilized, resuspended and boiled 
in 40 µL 1X lithium dodecyl sulfate (LDS)-phenol red 
sample buffer (26 mM Tris–HCl, 35 mM Trizma base, 
0.5% LDS, 2.5% glycerol, 0.125 mM EDTA, 0.04 mM 
phenol red). For Western blotting, 10 µL and 4 µL ID and 
IP fractions, respectively, were electrophoresed on precast 
4–12% Bis–Tris gels (ThermoFisher, Waltham, MA) with 
recombinant α-synuclein included as a loading control. 
Proteins were transferred onto 0.2 µm nitrocellulose at 
400 mA and 4 °C for 2 h, α-synuclein was detected using 
antibody C-20 (Supplementary Table 2) and bands were 
visualized using a LI-COR Odyssey CLx infrared imaging 
system (LI-COR, Lincoln, NE).
Tau
Tau was depleted from human brain extracts essentially 
as described for [67]. Freshly thawed extracts (1 mL) 
from PiD brain were first pre-cleared of endogenous IgG 
with 20 μl PGA beads for 1 h at 4 °C. PGA beads were 
sedimented out of solution (4000 × g for 5 min) and the 
supernatant divided into 0.5 mL aliquots. Each aliquot 
was treated with 10 µg Tau5 and 15 µL PGA, or 10 µg 
46–4 (isotype control) and 15 µL PGA and incubated with 
agitation overnight at 4 °C. Complexes were collected by 
centrifugation and washed 3 × 10 min in 1 mL PBS. To 
effectively deplete tau, extracts were subjected to three 
serial rounds of IP and a final PGA IP alone to remove 
unbound IgG. The IP’d tau was eluted by boiling in 15 μl 
of 2X LDS-phenol red sample buffer. For Western blot-
ting, 5 µL each ID and IP fractions were electrophoresed 
on precast 4–12% Bis–Tris gels (ThermoFisher, Waltham, 
MA) with recombinant hTau40 included as a loading con-
trol. Proteins were transferred onto 0.2 µm nitrocellulose at 
400 mA and 4 °C for 2 h, tau was detected using antibody 
K9JA (Supplementary Table 2) and bands were visualized 
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using a LI-COR Odyssey CLx infrared imaging system 
(LI-COR, Lincoln, NE).
Array tomography microscopy
Post-mortem human brain tissue was obtained from the Edin-
burgh Brain and Tissue Bank and the Massachusetts General 
Hospital Alzheimer’s Disease Research Center brain bank with 
full ethical approval (TSJ AMREC ethical approval number 
15-HV-016). The use of post-mortem human tissue for scien-
tific purposes has been approved by the Edinburgh Brain Bank 
ethics committee and the ACCORD (Academic and Clinical 
Central Office for Research and Development, collective office 
of the University of Edinburgh and the National Health Ser-
vice Lothian) committee for medical ethics AMREC. The 
Edinburgh Brain Bank is funded by the Medical Research 
Council with approval from the Research Ethics Committee 
(REC), (11/ES/0022). Tissue obtained was donated by indi-
viduals and their families, with ethical and legal approval. The 
tissue is collected, processed and embedded for array tomog-
raphy microscopy at autopsy as described previously [49]. 
Briefly, tissue from temporal cortex Brodmann area 20/21 was 
fixed in 4% paraformaldehyde for 2–3 h, dehydrated through 
an ethanol gradient and incubated overnight in LR White resin 
(Electron Microscopy Sciences) overnight at 53 °C. Samples 
were from cases with clinicopathological diagnoses of DLB 
(n = 3), AD, (n = 3) and FTD (n = 3) (Supplementary Table 1). 
In each case, a ribbon of at least ten 70 nm-thick consecu-
tive sections was produced using a histo jumbo diamond knife 
(Diatom) on an ultracut microtome (Leica), mounted on glass 
coverslips and stained as described previously [49]. Briefly, 
ribbons were stained with DAPI and antibodies to PrP plus 
synaptophysin and Aβ, αSyn, or phosphorylated tau (pTau) 
(Supplementary Table 2). Images were acquired from the same 
region of the temporal cortex on ten consecutive serial sections 
using a Leica TCS8 confocal with a 63 × 1.4 NA oil objec-
tive. Laser and detector settings were set on a positive control 
human post-mortem brain section which contained plaques, 
tangles or Lewy bodies. Alexa Fluor 488, Cy3 or Alexa Fluor 
647 were sequentially excited with the 488, 552 or 638 nm 
laser lines and imaged in 500 to 550 nm, 570 to 634 nm or 
649 to 710 nm spectral windows, respectively. A 405-nm laser 
was used for DAPI visualization collecting images in a spec-
tral range of 415 to 482 nm. Confocal images were aligned 
and segmented using a custom MATLAB algorithm (freely 
available at https ://githu b.com/array tomog raphy users /Array 
_tomog raphy _analy sis_tool). 3D reconstructions and visuali-
zation were made with FIJI [77], Paraview [3] and Inkscape 
(https ://www.inksc ape.org).
Results
Soluble aggregates of Aβ, α‑synuclein and tau bind 
to PrP
Extensive evidence indicates that soluble aggregates of 
synthetic Aβ bind to PrP. Most prior studies used ADDLs 
[19, 23, 31, 32, 66, 73, 84, 91, 93], a recipe-based prepa-
ration of Aβ1–42 which contains monomers, protofibrils 
and globular oligomers [39, 52, 66]. Here, we set out to 
determine if soluble aggregates of two other disease-linked 
proteins can also bind to PrP. Since the recipe used to 
generate ADDLs might not apply to other proteins, we 
first sought to establish protocols to enable generation 
of soluble aggregates of the three proteins of interest. 
Rather than try to trap intermediates of fibrillogenesis, 
we opted to use well-established, protein-specific condi-
tions to form end-stage fibrillar aggregates [14, 38, 68] 
and then liberate soluble aggregates from these insoluble 
materials using a standardized sonication protocol. For 
each protein the process began by using size exclusion 
chromatography (SEC)-isolated monomers (Fig. 1a–c). 
Thereafter, protein-specific conditions were employed to 
produce amyloid fibrils (Fig. 1d–f). Thioflavin-T (ThT) 
binding was used to monitor aggregation and  Tmax fibrils 
produced in the absence of ThT were sedimented, washed 
to remove monomers, then resuspended and sonicated to 
produce soluble aggregates of Aβ (SBAs; Fig. 1g), αSyn 
(SAAs; Fig. 1h) and tau (STAs; Fig. 1i). EM analysis of 
SPAs revealed fragmented, protofibrillar-like species, the 
majority of which were 16–40 nm in length (Fig. 1g–i; 
histograms to the right), and SPAs retained > 80% of the 
ThT-binding capacity found in Tmax fibrils (Fig. 1j–l).
The ability of different forms of Aβ, αSyn, and tau to 
bind recombinant  PrP23–231 was assessed using a solid-
phase assay. SBAs bound to  PrP23–231 with an average 
 EC50 of 38.9  nM, whereas neither Aβ monomers nor 
fibrils showed appreciable affinity for PrP (Fig. 2a). SAAs 
(Fig. 2b) and STAs (Fig. 2c) also bound to PrP in a satu-
rable manner with average  EC50s of 34.3 nM and 9.5 nM, 
respectively. Monomeric and fibrillar forms of αSyn and 
tau exhibited weak or no affinity for  PrP23–231. Thus, like 
Aβ, binding of αSyn and tau to PrP is aggregation state-
specific. Interestingly, STAs bound more tightly to PrP 
than SAAs or SBAs. In contrast, soluble aggregates of 
bovine serum albumin (BSA) bound very weakly to PrP.
Binding of Aβ to PrP is mediated by two distinct sites 
within the N-terminal half of PrP (Sites I and II, Sup-
plementary Fig. 1a) [19, 32, 53, 66]. To explore if bind-
ing of SAAs and STAs is mediated by the same sites on 
PrP, we tested whether mAbs directed to Site I (MI-0131) 
and Site II (ICSM35) (Supplementary Table  2) could 
 Acta Neuropathologica
1 3
prevent SPA binding. Both mAbs bound similarly well 
to PrP (Supplementary Figure 1e) and displaced SBAs to 
a comparable extent, with ICSM35 always slightly more 
effective (Fig. 2d). Interestingly, comparable  IC50 trends 
were observed for SAAs (Fig. 2e; ICSM35 = 5.2 nM and 
MI-0131 = 11.9 nM) and STAs (Fig. 2f; ICSM35 = 2.0 nM 
and MI-0131 = 5.0 nM). Since antibodies (~ 150 kDa) are 
large relative to PrP (~ 28 kDa), we further investigated 
binding of SPAs to PrP using deletion constructs lacking 
most of Site I  (PrP91–231) or both Sites I and II  (PrP119–231) 
(Supplementary Figure 1b-d). As expected, SBAs did not 
bind  PrP119–231 and weakly bound  PrP91–231 (Fig. 2g). Sim-
ilarly, SAAs and STAs showed little affinity for  PrP119–231 
and greatly diminished binding to  PrP91–231 (Fig. 2h, i). 
Indeed, for STAs, deletion of Site I  (PrP91–231) completely 
abolished binding (Fig. 2i). Collectively, deletion con-
struct and mAb displacement experiments indicate that 
binding of SBAs, SAAs and STAs require Sites I and II, 
but the relative importance of these sites differs depending 
on the particular SPA.
SPAs bind to neurons in a saturable and PrP‑dependent 
manner
Next, we determined whether different forms of Aβ, αSyn 
and tau could bind to the surface of cortical neurons and 
whether binding depended on PrP. Mouse primary neu-
rons (MPNs; Supplementary Fig. 2a) were incubated with 
monomers or SPAs for 2 h, washed extensively and stained 
using serial permeabilized immunocytochemistry (ICC)—
a method which avoids detection of endogenous Aβ, αSyn 
and tau (Supplementary Figure 2b and c). Incubation of 
WT MPNs with SPAs revealed clear dose-dependent bind-
ing (Fig. 3a, c, e), whereas monomeric proteins, even when 
tested at 3000 nM, did not bind MPNs (Supplementary Fig-
ure 2d–f). Quantification of co-localized PrP-immunoreactive 
Fig. 1  Preparation and characterization of soluble aggregates of 
Aβ, α-synuclein and tau. a–c Representative chromatograms depict-
ing isolation of monomeric (a) Aβ1–42, (b) α-synuclein (αSyn), and 
(c) tau. Downward arrows indicate elution of globular molecular 
weight standards, the shaded region indicates the fraction retained for 
aggregation experiments and the inset SDS-PAGE/coomassie (CBB) 
depicts migration of the purified monomers. d–f Freshly SEC-iso-
lated monomer was diluted to 20 µM (Aβ1-42; d) and 35 µM (αSyn; 
e) and 50 µM (tau; f), combined with Thioflavin-T (ThT) and aggre-
gation monitored until ThT signals plateaued (Tmax). Aβ and αSyn 
were aggregated without additives while tau was aggregated in the 
presence of 50 and 100 µM heparin and DTT, respectively. Binding 
of ThT to Aβ1–42 and αSyn was monitored continuously, whereas ali-
quots of tau were removed, mixed with ThT and assessed at 3-day 
intervals. In each case, identical reactions without protein (buffer) 
served as negative control. Fibrils were harvested at time points 
indicated by downward arrows, mounted on grids and representative 
negative-stain electron microscope (EM) micrographs of Aβ, αSyn 
and tau Tmax fibrils are presented to the right of each graph. g–i Rep-
resentative negative-stain EM micrographs of immersion sonicated 
soluble aggregates (Aβ SBAs, g; αSyn SAAs, h; tau STAs, i). Size 
distribution of SBAs, SAAs and STAs as determined by negative-
stain EM are presented to the right of each micrograph. j–l Neat Tmax 
fibrils (N), the supernatant of centrifuged fibrils (S), resuspended 
washed fibril pellets (P), and SBAs (j), SAAs (k), and STAs (l) were 
used for ThT binding. Buffer alone (B) and freshly isolated monomer 
(M) were included as negative controls. Scale bar in micrographs 
from d–i = 100 nm. Data in d–f and j–l are the mean ± SD, indicate 
three technical replicates and are representative of at least three inde-
pendent experiments. Molecular weight markers (in kDa) are indi-
cated to the right of the inset CBB gels in a, b and c 
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(IR) and SPAs-IR puncta confirmed that binding of SBAs 
(Fig. 3b), SAAs (Fig. 3d) and STAs (Fig. 3f) to MPNs was 
dose-dependent and saturable. Of note, we did not monitor 
binding of fibrils to MPNs because it is not possible to gen-
erate soluble preparations of fibrils and because fibrils can 
nonspecifically precipitate onto membranes.
To determine if binding of SPAs to neurons required PrP, 
we employed the same serial permeabilized ICC protocol as 
used above, this time on MPNs prepared from WT and PrP-
null (Prnp−/−) mice (Supplementary Figure 3a). DIV21 MPNs 
were incubated with 500 nM SPAs for 2 h, washed and pro-
cessed. Quantification of SBAs-IR puncta revealed a > 50% 
reduction in binding to Prnp−/− MPNs relative to WT (Fig. 4a, 
b). Strikingly, SAAs-IR and STAs-IR puncta were similarly 
reduced in Prnp−/− MPNs (Fig. 4c–e). Using on-cell Western 
blotting to monitor SPAs binding to MPNs, we also found 
dose-dependent binding of SPAs to WT MPNs and reduced 
binding to Prnp−/− neurons (Supplementary Figure 3b–d). 
Furthermore, transfection of WT MPNs with short-hairpin 
RNAs (shRNA) targeting the 5′-untranslated region of Prnp 
(shPrP; Supplementary Figure 4a and b) greatly attenuated 
binding of SBAs (Supplementary Figure 4c), SAAs (Supple-
mentary Figure 4d) and STAs (Supplementary Figure 4e) to 
the surfaces of neurons.
PrP is required for SPA‑mediated neuritotoxicity 
and synaptotoxicity
We recently developed a medium-throughput, live-cell imag-
ing assay to monitor the effects of Aβ on neuritic integrity 
Fig. 2  Soluble aggregates of Aβ, α-Synuclein and Tau bind to the 
N-terminus of PrP. a–c Binding of Aβ (a), αSyn (b) and tau (c) 
monomers, soluble aggregates and fibrils to immobilized  PrP23–231 
was assessed using an ELISA-like microtiter plate assay. Data shown 
are the mean ± SD from a single experiment, whereas inset  EC50s 
are from at least four independent experiments. d–f Binding of solu-
ble protein aggregates to immobilized  PrP23–231 can be inhibited by 
anti-PrP monoclonal antibodies (mAbs) to Sites I (MI-0131) and II 
(ICSM35), but not a nonspecific mAb (46–4). Data shown are the 
mean ± SD from a single experiment, whereas inset  IC50s are from 
at least four independent experiments. g–i To determine the regions 
of PrP involved in binding soluble protein aggregates,  PrP23–231, 
 PrP91–231, and  PrP119–231 were immobilized and binding of SBAs (g), 
SAAs (h) and STAs (i) measured. Data shown are the mean ± SD 




[41, 45]. Here, we adapted this platform to assess whether 
SPAs or their corresponding monomers are toxic to neurons. 
WT MPNs were incubated with 250, 500 and 1000 nM SBAs, 
SAAs, STAs, or monomers and neurite length monitored for 
96 h. Even at the highest concentrations tested, Aβ, αSyn and 
tau monomers had no effect on neurite length. In contrast, 
SBAs impaired neurons in a time- and dose-dependent man-
ner (Fig. 5a, b), and highly similar effects were observed with 
SAAs (Fig. 5c, d) and STAs (Fig. 5e, f). Strikingly, when 
tested alongside WT MPNs, Prnp−/− cells were resistant to 
SBAs (Fig. 5g), SAAs (Fig. 5h) and STAs (Fig. 5i).
Neuritic loss is a common and early facet of all neuro-
degenerative diseases, likely preceded by functional altera-
tions. To assess the effects of SPAs on synaptic function, 
we measured long-term potentiation (LTP) in the Schaffer 
collaterals of mouse hippocampal slices treated with SPAs 
(Fig. 6a–c and Supplementary Figure 5a–c). We found that 
SBAs, SAAs and STAs inhibited TBS-induced LTP in a 
dose-dependent fashion, with SBAs and SAAs causing a 
significant inhibition at 250 nM. Unlike SAAs and SBAs, 
when STAs were tested at concentrations greater than 50 nM 
they completely blocked LTP. Hence, we explored lower 
concentrations and found that STAs caused a robust block of 
LTP at 2 nM. Critically, when Prnp−/− slices were exposed 
to SPAs at concentrations which blocked LTP in WT slices 
there was no diminution of LTP. Thus, the SPA-mediated 
impairment of synaptic plasticity requires expression of PrP 
(Fig. 6d–f and Supplementary Figure 5d–f).
We previously reported that neurotoxic Aβ species iso-
lated from AD brain impair LTP by binding directly to the 
presynapse [90]. Since PrP is enriched in synaptic com-
partments [40], we monitored colocalization of PrP and 
Aβ, αSyn or tau in tissue sections from three patients each 
who died with AD, dementia with Lewy body (DLB) and 
frontotemporal dementia (FTD) (Supplementary Table 1). 
Using high-resolution array tomography we found that 
presynaptic, synaptophysin-positive PrP colocalized with 
all three pathological proteins in end-stage disease brain 
Fig. 3  SBAs, SAAs and STAs bind to primary neurons in a dose-
dependent and saturable manner. a, c, e Soluble protein aggregates 
were added to primary mouse neurons (MPNs) and binding assessed 
using serial-permeabilized immunocytochemistry. Representative 
images SBAs (a), SAAs (c) and STAs (e) are shown. Staining for 
MAP2, PrP and bound proteins are shown in blue, red and yellow, 
respectively. b, d, f Relative dose–response binding of SBAs (a), 
SAAs (c) and STAs (e) to MPNs was quantified using a custom FIJI 
macro that identified soluble protein aggregate puncta that were at 
least 50% PrP colocalized. Relative values were determined by nor-
malizing binding signals to those obtained with the highest protein 
concentration analyzed (3  µM). Inset images depict enlarged triple-
colocalization images for neurons treated with 1 μM SPAs (from a, 
c and e). Scale bar in a, c and e = 50 µm, and data in b, d and f rep-




(Supplementary Figure  6a and b). These human data, 
together with our in vitro cell-binding data (Figs. 3, 4 and 
Supplementary Figures 3 and 4), provide strong evidence 
of direct binding of SPAs with PrP.
An all‑human experimental paradigm demonstrates 
that SPA‑mediated toxicity requires  PrPC
To further examine the disease relevance of our experi-
ments we utilized human iPSC-derived neurons (iNs) [96], 
employing CRISPR-edited isogenic lines expressing or 
lacking PRNP. CRISPR-Control (CR-C) iNs and CRISPR-
PRNP-null (CR-PRNP) iNs showed a similar time-depend-
ent elaboration of processes and were otherwise indistin-
guishable (Supplementary Figure 7A–C and F), except 
PrP null iNs lacked PrP (Supplementary Figure 7d and 
e). Importantly, when treated with equimolar concentra-
tions (500 nM) of SBAs, SAAs and STAs, CR-C iNs, like 
WT MPNs, were susceptible to SPA-mediated toxicity. In 
contrast, SPAs had no measurable effect on CR-PRNP iN 
Fig. 4  SBAs, SAAs and STAs bind to primary neurons in a PrP-
dependent manner. a, c and e Soluble protein aggregates were 
added to wild-type (WT) and PrP-null (Prnp−/−) MPNs and binding 
assessed using serial-permeabilized immunocytochemistry. Repre-
sentative images for SBAs (a), SAAs (c) and STAs (e) are shown. 
Staining for MAP2, PrP and bound proteins are shown in blue, red 
and yellow, respectively. Enlarged triple-colocalization images, indi-
cated by boxed regions, are presented to the right of each panel. b, d 
and f, Relative binding of SBAs (b), SAAs (d) and STAs (f) to WT 
and Prnp−/− MPNs was determined as in Fig. 3. Binding of soluble 
protein aggregates to Prnp−/− MPNs is expressed as % binding to WT 
neurons. Scale bar in a, c and e = 50 µm, and data in b, d and f are the 
mean ± SD and represent three independent experiments with 45–300 
images analyzed per experiment per genotype
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neurite length (Fig. 7a–c). Moreover, when CR-C iNs were 
treated with very high (10 μM) concentrations of soluble 
aggregates formed from bovine serum albumin, no effects on 
neuronal or neuritic health were observed (Supplementary 
Figure 8a and b).
Next, we assessed whether the two N-terminal PrP mAbs 
found to prevent SPA binding in our solid-phase PrP binding 
assays could attenuate SPA-induced loss of neuritic integrity. 
500 nM SBAs, SAAs and STAs produced robust neuritotox-
icity in iNs (Fig. 7d–f), whereas iNs pretreated with 3 µg/
mL MI-0131 or ICSM35 were protected from these effects 
(Fig. 7d–f). Collectively, these results indicate that although 
cell surface PrP is necessary for only half of SPAs binding, 
PrP is required for all of the SPAs-induced neuritotoxicity.
In previous studies, we found that aqueous extracts 
from AD brains impair memory consolidation, long-term 
potentiation (LTP), synaptic and neuritic structures and that 
these effects can be prevented by immunodepletion (ID) of 
Aβ [32, 41, 80]. In one case, we found that a single AD 
brain extract blocked LTP in a tau-dependent manner [67]. 
However, this extract was the exception rather than the rule. 
Here, we investigated the activity of soluble proteins present 
in aqueous extracts prepared from the brains of seven clini-
cally and neuropathologically distinct humans: an individual 
who died cognitively intact and free of neurodegeneration 
and two patients each who died with end-stage AD, DLB 
and PiD (Supplementary Table 1). The procedure used to 
generate extracts was identical, but disease-specific brain 
regions were used to reflect the well-established selective 
vulnerability associated with AD, DLB and PiD. The AD 
brain extracts were ID’ed of Aβ using the anti-Aβ antise-
rum AW7, whereas the DLB and PiD extracts were ID’ed 
Fig. 5  SBAs, SAAs and STAs are toxic to primary neurons in a 
manner requiring PrP. a, c and e, WT MPNs were incubated with-
out (Media), with monomers (1  μM), or with SBAs (a), SAAs (c) 
and STAs (e) and neurite length measured using live-cell imaging. 
Each well was imaged for 6 h prior to the addition of samples, and 
NeuroTrack-identified neurite lengths were used to normalize values 
obtained across 96 h after sample addition. Each point represents the 
mean ± SEM of four images taken from three independent wells. b, d, 
f Plots of normalized neurite length for WT PMNs incubated without 
(Media), with monomers (1  μM), or with SBAs (b), SAAs (d) and 
STAs (f). Data are derived from the last 6 h of the traces shown in 
a, c and e, respectively. Each point represents the mean ±  SEM of 4 
images from three wells for each 2 h bin. g, h, i Plots of normalized 
neurite length for WT and PrP-null (Prnp−/−; gray shading) MPNs 
incubated without (Media) or with SBAs (g), SAAs (h) and STAs (i). 
Data are derived from the last 6 h of treatment. Each point represents 
the mean ± SEM of four images from three wells for each 2  h bin 
from three independent experiments
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of αSyn and tau using mAbs 2F12 and Tau5 (Supplemen-
tary Table 2), respectively (Supplementary Figure 9). Three 
rounds of AW7-ID effectively removed 96% (AD1) and 
97% (AD2) of the detectable Aβ as determined by x-42 
MSD immunoassay (Fig. 8a, c) and Western blot (Supple-
mentary Figure 9b; AD2). Importantly, AW7 ID did not 
markedly alter ELISA-measured tau levels, e.g. in AD2 
tau measured 3.95 ± 0.62 μg/mL in the mock ID sample 
and 2.87 ± 0.21 μg/mL in the AW7 ID’d sample). Due to 
the higher abundance of αSyn compared with Aβ or tau, 
a column-based batch IP method was employed (Supple-
mentary Figure 9c) and this removed all ELISA (Fig. 8e, 
g) and Western blot (Supplementary Figure 9D; DLB2) 
detectable αSyn from the DLB extracts. Three rounds of 
Tau5-ID effectively removed 78% (PiD1) and 65% (PiD2) 
of tau by mid-region ELISA (Fig. 8i, k), approximately 50% 
of phosphorylated tau in both extracts by phospho-Thr181 
ELISA (PiD1 mock ID, 96.42 ± 1.26 ng/m; PiD1 Tau5 ID, 
53.77 ± 3.36 ng/mL and PiD2 mock ID, 55.85 ± 1.47 ng/mL; 
PiD2 Tau5 ID, 21.84 ± 0.41 ng/mL) and near complete loss 
of the ~ 49–55 kDa bands in the Tau5 ID fraction by Western 
blot (Supplementary Figure 9e; PiD2).
Thereafter, we used our iN live-cell imaging paradigm 
to test the effects of these extracts. When used at a final 
dilution of 1:8, each of the extracts from diseased brains 
induced neuritotoxicity (Fig. 8b, d, f, h, j, l) while an extract 
from a subject who died free of neurodegeneration did not 
(Supplementary Figure 8d). ID of Aβ from the AD brain 
extracts rescued neuritotoxicity (Fig. 8b, d), as did ID of 
αSyn from the DLB brain extracts (Fig. 8f, h), and ID of tau 
from the PiD brain extracts (Fig. 8j, l). To determine if PrP 
was involved in the observed toxicity, CR-PRNP iNs were 
exposed to mock-ID extracts. Strikingly, in three separate 
experiments, knock-out of PrP protected iNs from neurito-
toxicity mediated by the extracts of AD, DLB and PiD brains 
(Fig. 8d, h, l, shaded regions). These unambiguous findings 
imply a central role for PrP in SPA-mediated toxicity.
Fig. 6  PrP is required for SPA-mediated inhibition of LTP. Field 
excitatory postsynaptic potential (fEPSP) were recorded simultane-
ously from sets of four slices using a MED64 Quad II system. a–c 
Time-course traces show that SBAs (a), SAAs (b) and STAs (c) 
dose-dependently inhibit hippocampal LTP in wild-type (WT) slices. 
In a and b, aCSF control (Ctr), black; 50  nM SPAs, grey; 100  nM 
SPAs, blue; 250 nM SPAs, green; and 500 nM SPAs, red. In c, aCSF 
control (Ctr), black; 0.5  nM SPAs, gray; 1  nM SPAs, blue; 2  nM 
SPAs, green; and 10 nM SPAs, red. d–f Time-course traces indicate 
that SBAs (d; 500 nM) and SAAs (e; 500 nM) and STAs (f; 10 nM) 
potently inhibit LTP in WT, but not PrP-null (Prnp−/−), slices. aCSF 
control on WT slices (WT Ctr), black; aCSF control on Prnp−/− (KO 
Ctr) slices, gray; SPAs on WT slices, red; SPAs on Prnp−/− slices, 
blue. In a–f, the gray horizontal bar represents the duration of SPA 
treatment and data represent the mean ± SD of 5–6 animals per group. 




Prion diseases typically involve a long, silent period of PrP 
aggregation and propagation, and an explosive symptomatic 
phase which results from acute neurotoxicity [1, 54, 75]. 
While the mechanism(s) causing neuronal loss are not yet 
resolved it is clear that membrane-bound  PrPC is required 
[12, 48, 58, 65] and binding of misfolded PrP to  PrPC is 
a critical step [11]. β-sheet rich assemblies formed from 
design peptides, yeast prion and Aβ, can also bind to  PrPC 
and cause neuronal compromise [74]. This raises the intrigu-
ing possibility that  PrPC may contribute to other proteinopa-
thies by facilitating a neurotoxic signaling cascade [7, 74].
Mindful of the inconsistencies which have plagued the 
study of protein aggregation and confounded assessment 
of bioactivity [8, 79, 89], we developed a standardized 
protocol to prepare soluble aggregates and accurately 
determine their concentration. For this we exploited our 
highly reproducible system [38] which has been used to 
elucidate the microscopic events underlying Aβ aggre-
gation [2, 21]. Central to our approach was the use of 
rigorously controlled conditions which yield highly 
homogenous end-stage protein aggregates, their solubi-
lization using a standardized sonication procedure, and 
careful quantitation using validated ELISAs. This not only 
allowed us to accurately compare the binding and toxicity 
of monomers, soluble aggregates and fibrils formed by a 
single protein, but also those formed by different proteins.
Using a sensitive ELISA-like assay and binding to PrP-
expressing and -deficient cells, we demonstrate that solu-
ble aggregates of Aβ, αSyn and tau readily bind to PrP, 
whereas corresponding monomers and fibrils show little 
affinity. Across multiple experiments, SBAs and SAAs 
showed similar binding  (EC50 ~ 30 nM) to full-length PrP, 
whereas STAs consistently showed slightly tighter bind-
ing  (EC50 ~ 10 nM). It is interesting to speculate that this 
stronger binding might be related to the more potent block 
of LTP exerted by STAs compared with SBAs and SAAs. 
Heparin is known to bind PrP [17] and the heparin used 
to induce tau aggregation could potentially explain the 
enhanced binding of STAs to PrP. However, this is unlikely 
since a sensitive assay detected no heparin in the tau fibrils 
used to produce STAs. Moreover, fibrils that were formed 
in the presence of heparin, but not solubilized, bound only 
weakly to PrP. Notably, fibrils produced from recombi-
nant monomer formed both straight and twisted filaments 
analogous to species found in human tauopathies. Thus, it 
Fig. 7  SBAs, SAAs and STAs are toxic to induced neurons in a man-
ner requiring PrP. a–c iPSC-derived human neurons (iNs) express-
ing (CR-C) or lacking PrP (CR-PRNP; gray shading) were incu-
bated without (Media) or with SBAs (a), SAAs (b) and STAs (c) 
and neurite length measured using live-cell imaging. The CR-PRNP 
line was generated using CRISPR editing (Supplementary Figure 6). 
Data were collected and analyzed as in Fig.  5 and represent the 
mean ± SEM of four images from three wells for each 2 h bin from 
three independent experiments. d–f To determine whether immuno-
targeting PrP could protect against neurotoxicity induced by soluble 
protein aggregates, iNs were treated with or without anti-PrP mAbs 
to Site I (MI-0131) or II (ICSM35) before the addition of SBAs (d), 
SAAs (e) and STAs (f) and neurite length measured using live-cell 
imaging. Data were collected and analyzed as in Fig. 5 and represent 
the mean ± SEM of four images from three wells for each 2  h bin 
from three independent experiments
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is unlikely end-stage tau fibrils, regardless of the methods 
used for their generation or purification, interact with PrP.
Use of deletion constructs revealed some differences in 
SPA binding to PrP. SBAs exhibited appreciable binding to 
a construct,  PrP91–231, which lacks binding Site I and retains 
binding Site II. In contrast, neither SAAs nor STAs bound 
 PrP91–231 to a significant extent. Why this should be is as yet 
unclear, but likely derives from ultrastructural differences 
between SBAs, SAAs and STAs. Conversely, when applied 
to cortical neurons there was no discernible difference in 
binding or toxicity of the three different SPAs. The inability 
to detect a difference in binding to neurons is understand-
able given that approximately 50% of SPA binding is not 
mediated by PrP and that ICC is less quantitative than our 
Fig. 8  Soluble extracts from AD, DLB and PiD brains are toxic to 
neurons in a manner requiring PrP. a Aβx−42 immunoassay quanti-
fication of Aβ present in homogenates from AD1 brain after immu-
nodepletion with AW7 (AW7 ID) or preimmune serum (Mock). 
b iNs were incubated without (Media) or with extracts from brain 
AD1 ID’ed with AW7 (AW7 ID) or preimmune serum (Mock) and 
neurite length measured using live-cell imaging. c Aβx−42 immuno-
assay quantification of Aβ present in homogenates from AD2 brain 
after immunodepletion with AW7 (AW7 ID) or preimmune serum 
(Mock). d iNs expressing (CR-Control; circles) or lacking PrP (CR-
PRNP; diamonds, grey shading) were incubated without (Media) or 
with extracts from brain AD2 ID’ed with AW7 or preimmune serum 
(Mock) and neurite length measured using live-cell imaging. e ELISA 
quantification of αSyn present in homogenates from DLB1 brain 
after ID with 2F12 (2F12 ID) or isotype control (Mock). f iNs were 
incubated without (Media) or with extracts from brain DLB1 ID’ed 
with 2F12 (2F12 ID) or isotype control (Mock) and neurite length 
measured using live-cell imaging. g ELISA quantification of αSyn 
present in homogenates from DLB2 brain after ID with 2F12 (2F12 
ID) or isotype control (Mock). h CR-Control and CR-PRNP iNs were 
incubated without (Media) or with extracts from brain DLB2 ID’ed 
with 2F12 (2F12 ID) or isotype control (Mock) and neurite length 
measured using live-cell imaging. i ELISA quantification of tau pre-
sent in homogenates from PiD1 brain after ID with Tau5 (Tau5 ID) 
or isotype control (Mock). j iNs were incubated without (Media) or 
with extracts from brain PiD1 ID’ed with Tau5 (Tau5 ID) or isotype 
control (Mock) and neurite length measured using live-cell imaging. 
k ELISA quantification of tau present in homogenates from PiD2 
brain after ID with Tau5 (Tau5 ID) or isotype control (Mock). l, CR-
Control and CR-PRNP iNs were incubated without (Media) or with 
extracts from brain PiD2 ID’ed with Tau5 (Tau5 ID) or isotype con-
trol (Mock) and neurite length measured using live-cell imaging. In a, 
c, e, g, i and k, data represent the mean ± SD of three technical repli-
cates and are representative of at least two independent experiments. 
In b, d, f, h, j and l, data were collected and analyzed as before and 
represent the mean ± SEM of four images from three wells for the last 
6 h of three independent experiments
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ELISA-like assay. Co-immunoprecipitation is a common 
method used to probe for interactions between endogenous 
proteins. However,  PrPC is a membrane-attached protein that 
requires the use of strong detergents for its solubilization 
making it difficult to identify non-covalent interactions sen-
sitive to detergents.
Importantly, both the plasticity disruption and neurito-
toxicity induced by SPAs were completely absent when PrP 
was ablated. Though probing the mechanism by which PrP 
mediates these effects is beyond the scope of the current 
study, it is interesting to note that the PrP is known to com-
plex with metabotropic glutamate receptors (mGluRs) and 
that mGluRs have been linked to PrP-mediated disruption of 
LTP [43, 84] and changes in neuritic architecture [9]. Indeed, 
our data indicate that all three SPAs caused LTP and struc-
tural impairments, albeit to different extents. For example, 
we observed that, relative to other SPAs, STAs bind tighter 
to PrP and impair LTP at much lower concentrations. How-
ever, equimolar concentrations of SPAs cause nearly equal 
neuritotoxicities. One possible explanation for this is the 
differences between acute slice physiology and in vitro cell-
structural models and the fact that physiological changes 
are thought to precede structural alterations. Regardless, the 
lack of effect of SPAs on PrP-null hippocampal slices and 
dissociated neurons indicates that the effect of SPAs on WT 
cells is not a consequence of mechanical disruption since 
membranes should be equally susceptible to pore forming 
assemblies irrespective of PrP expression. This does not 
exclude the possibility that other forms of Aβ, αSyn and tau 
can induce toxicity by PrP-independent mechanisms. None-
theless, the fact that extracts from diseased brains cause neu-
ritoxicity in a PrP-dependent manner strongly suggests that 
the bioactive forms of SPAs present in human brain share 
some similarity with SPAs generated in vitro. Moreover, 
our finding that PrP antibodies prevent AD, DLB and PiD 
brain-induced toxicity argues against the lack of toxicity in 
PrP null neurons being due to unknown protective effects of 
constitutive PrP ablation. Similarly, amelioration of toxicity 
by immunodepletion with antibodies specific for Aβ, αSyn 
and tau demonstrates the involvement of these proteins. Fur-
thermore, the lack of effect of control brain extracts rich in 
αSyn and tau indicates that the toxicity seen with DLB and 
PiD brain extracts is imparted by disease-specific, presum-
ably aggregated, forms of these proteins.
While numerous studies have demonstrated that soluble 
aggregates of Aβ can bind to PrP and induce a range of toxic-
ities, much less is known about whether αSyn and tau inter-
act with PrP. A paper published during the submission of our 
manuscript claimed to have been able to co-IP PrP, APP, Aβ 
and phospho-tau from transgenic mouse and human brain 
[34]. Here, we show direct binding of tau to PrP in vitro, 
that this interaction is aggregation-dependent and necessary 
for SPA-mediated disruption of LTP and neuritotoxicity. 
Moreover, we provide complementary evidence of binding 
using mouse primary neurons, iPSC-derived human neurons, 
and array tomography of diseased brains, that together sub-
stantiate the in vivo relevance of the SPA-PrP interaction. 
Two previous studies investigated binding of αSyn to PrP 
[29, 86], both of which used what they referred to as oli-
gomers. Intriguingly, the preparation used in the study that 
reported toxicity mediated by αSyn that was not dependent 
on  PrPC appeared as imperfect spheres with average diam-
eters less than 20 nm [86]. Comparable structures are formed 
by Aβ and these too bind only weakly to PrP, and like αSyn 
pseudo-spheres mediate toxicity independent of  PrPC [66]. 
In contrast, short Aβ fibrils and protofibrils, similar to our 
SAAs, SBAs and STAs, bind to PrP and require  PrPC to 
induce toxicity [66]. Collectively, these results suggest that 
protofibrils are the principle species which bind to PrP and 
mediate toxicity via  PrPC. A prior study reported that αSyn 
oligomers induced PrP-dependent toxicity in a number of 
different paradigms, but the authors did not provide detailed 
analysis of the active αSyn preparation and used antibodies 
(without validating binding activity) to infer potential PrP 
binding sites. Here, we employed well-validated antibodies 
and deletion constructs to systematically demonstrate that 
SAAs, but not αSyn monomer or fibrils, bind to PrP and that 
binding was mediated via binding Sites I and II. Moreover, 
SPAs which bind PrP caused neuritotoxicity and impairment 
of LTP, while monomers and fibrils did not. Thus, our results 
clearly link PrP binding with toxicity.
When breaking ground in a new area no single study 
can answer all the questions raised by novel findings, nor 
apply the full gambit of approaches in the armamentarium 
of modern biomedicine. So it is with our study. While we 
have unambiguously demonstrated that both recombinant 
and human brain-derived forms of Aβ, tau and αSyn can 
bind to PrP and induce functional and structural deficits, this 
important beachhead requires strengthening and expansion. 
It will fall to future studies to purify soluble protein aggre-
gates from diseased brain and to test their toxic activities. In 
this regard, our recent observation that recombinant PrP N1 
can protect against the toxicity of brain-derived Aβ [62] sug-
gests that PrP derivatives such as N1 may serve as affinity 
reagents to enable the isolation and molecular identification 
of SPAs. Similarly, in vivo studies will be required to fur-
ther investigate the translational nature of our work. Namely, 
experiments in tau and αSyn transgenic mice should test the 
value of targeting PrP, by genetic knock-out, or knock-down, 
or use of anti-PrP antibodies. In this era when antisense oli-
gonucleotide and RNAi technologies are being successfully 
applied for treatment of what were previously thought to 
be incurable diseases [55], experiments in mice could be a 
prelude to knocking-down  PrPC expression in humans [65]. 
Such an approach is supported by the fact that loss of one 
 PrPC allele is well tolerated in humans [63]. Thus, given 
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our work suggests that targeting  PrPC could be of benefit 
in several neurodegenerative diseases we recommend the 
exploration of  PrPC as a therapy which could be particularly 
useful in individuals with evidence of mixed pathologies.
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